IRVING, Texas, Feb. 2, 2012 (GLOBE NEWSWIRE) -- Caris Life Sciences™, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality molecular profiling and blood-based diagnostic services, recently presented a clinical poster at the 2012 Multidisciplinary Head & Neck Cancer Symposium. The poster entitled, “Biomarker expression in Head and Neck Squamous Cell Carcinoma (HNSCC) – Implications for Therapy,” demonstrated the clinical value of molecular profiling in helping physicians develop individualized cancer treatment strategies for this aggressive tumor type with an often unpredictable prognosis. This study retrospectively reviewed data aggregated from tumors molecularly profiled with Caris Target Now.
